LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the closing of its public offering of 12,650,000 shares of common stock, offered at a price to the public of $6.30 per share, which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares of common stock. This exercise brings the net proceeds in the offering to approximately $74.6 million, after deducting underwriting discounts and commissions and expenses payable by Agenus.
Help employers find you! Check out all the jobs and post your resume.
